Remove Hemorrhage Remove Strokes Remove Thrombolysis
article thumbnail

SHINE Trial Sheds Light on Deadly Stroke Complication

DAIC

UVA Health's Karen Johnston, MD, the SHINE trial leader, was pleased to see the new insights into best practices for stroke care. These data from the SHINE trial continue to inform the national stroke community about potential approaches to treating hyperglycemic stroke patients to assure better outcomes,” she said.

Stroke 105
article thumbnail

Intravenous Thrombolysis for Acute Ischemic Stroke in Patients With Recent Direct Oral Anticoagulant Use: A Systematic Review and Meta?Analysis

Journal of the American Heart Association

BackgroundIntravenous thrombolysis (IVT) is an effective stroke therapy that remains underused. Outcomes included symptomatic intracranial hemorrhage, any intracranial hemorrhage, serious systemic bleeding, and 90‐day functional independence (modified Rankin scale score 0–2). 1.36]), any intracranial hemorrhage (17.7

article thumbnail

Arterial Connections Improve Treatment Outcomes Following Stroke

DAIC

Kulcsar, University Hospital Zurich milla1cf Mon, 02/26/2024 - 12:13 February 26, 2024 — Ischemic strokes are a major health burden. Many stroke patients recover poorly despite timely treatment To treat these symptoms and restore blood flow to the brain, the obstructed vessel needs to be “declogged”, or recanalized.

article thumbnail

Findings from MOST Trial Presented at ISC24: Blood thinners added to clot-busting medication did not improve stroke outcomes

DAIC

Findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial were presented on the first day of the American Stroke Association’s International Stroke Conference, ISC 2024, being held through Feb. A lot of our approaches in stroke treatment were learned from how we treat heart attacks.

Stroke 105
article thumbnail

Abstract WP20: Hemorrhagic Conversion Patterns After Stroke Thrombolysis With Alteplase versus Tenecteplase Real-World Experience

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page AWP20-AWP20, February 1, 2024. Importance:Tenecteplase use is more prevalent as the thrombolytic drug of choice for acute ischemic stroke, with results demonstrating its non-inferiority compared to alteplase. Results:Median age was 62.94 for alteplase and 64.45

article thumbnail

Comparing Low- or Standard-Dose Alteplase in Endovascular Thrombectomy: Insights From a Nationwide Registry

Stroke Journal

Stroke, Ahead of Print. BACKGROUND:Timely intravenous thrombolysis and endovascular thrombectomy are the standard reperfusion treatments for large vessel occlusion stroke. 0.98]), a numerically higher incidence of symptomatic intracerebral hemorrhage (6.7% mg/kg alteplase).METHODS:We mg/kg alteplase).METHODS:We

article thumbnail

Thrombolysis for Wake-Up Stroke Versus Non–Wake-Up Unwitnessed Stroke: EOS Individual Patient Data Meta-Analysis

Stroke Journal

Stroke, Ahead of Print. Background:Stroke with unknown time of onset can be categorized into 2 groups; wake-up stroke (WUS) and unwitnessed stroke with an onset time unavailable for reasons other than wake-up (non–wake-up unwitnessed stroke, non-WUS). Death occurred in 4.0% and 0.3%, respectively (P=0.194).